<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> (TZDs) are neuroprotective in rodent <z:hpo ids='HP_0001297'>stroke</z:hpo> models using intra-peritoneal, intra-venous and inter-ventricular routes of administration.We tested if oral <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> at doses similar to those used by humans to treat <z:mp ids='MP_0002055'>diabetes</z:mp> reduces infarction volume following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in the rat </plain></SENT>
<SENT sid="1" pm="."><plain>Rats were fed DMSO or <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (0.65 mg/kg equivalent to a 45 mg dose in a 70 kg man, 0.40 mg/kg equivalent to a 30 mg dose or 0.20mg/kg to a 15 mg dose) dissolved in DMSO daily for five days prior to 2 hour MCAO </plain></SENT>
<SENT sid="2" pm="."><plain>Animals underwent serial functional analysis using the modified neurologic <z:hpo ids='HP_0001297'>stroke</z:hpo> scale (mNSS), the adhesive sticker test and the inclined plane, <z:hpo ids='HP_0000001'>all</z:hpo> of which test motor sensory function </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty one days later, MCAO rats were sacrificed and <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes determined </plain></SENT>
<SENT sid="4" pm="."><plain>We found significant reductions in the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume using the 0.65 and 0.40 mg/kg dose </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, these rats had improved performance on behavioural assays </plain></SENT>
<SENT sid="6" pm="."><plain>The 0.20mg/kg dose did not significantly reduce infarction volume or improve behaviour </plain></SENT>
</text></document>